⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LRMR News
Larimar Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
LRMR
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
globenewswire.com
LRMR
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
globenewswire.com
LRMR
Form 8-K
sec.gov
LRMR
Form 8-K
sec.gov
LRMR
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
globenewswire.com
LRMR
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
globenewswire.com
LRMR
Form 8-K
sec.gov
LRMR
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
LRMR
Form 8-K
sec.gov
LRMR